- Home
- FULC vs TTGT Comparison
FULC vs TTGT Comparison
Compare FULC & TTGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FULC
- TTGT
- Stock Information
- Founded
- FULC 2015
- TTGT 1999
- Country
- FULC United States
- TTGT United States
- Employees
- FULC N/A
- TTGT N/A
- Industry
- FULC Biotechnology: Pharmaceutical Preparations
- TTGT Telecommunications Equipment
- Sector
- FULC Health Care
- TTGT Telecommunications
- Exchange
- FULC Nasdaq
- TTGT Nasdaq
- Market Cap
- FULC 469.0M
- TTGT 468.3M
- IPO Year
- FULC 2019
- TTGT 2007
- Fundamental
- Price
- FULC $8.73
- TTGT $5.61
- Analyst Decision
- FULC Buy
- TTGT Strong Buy
- Analyst Count
- FULC 6
- TTGT 5
- Target Price
- FULC $8.67
- TTGT $16.40
- AVG Volume (30 Days)
- FULC 524.6K
- TTGT 812.6K
- Earning Date
- FULC 11-12-2025
- TTGT 11-10-2025
- Dividend Yield
- FULC N/A
- TTGT N/A
- EPS Growth
- FULC N/A
- TTGT N/A
- EPS
- FULC N/A
- TTGT N/A
- Revenue
- FULC N/A
- TTGT $387,100,000.00
- Revenue This Year
- FULC N/A
- TTGT N/A
- Revenue Next Year
- FULC N/A
- TTGT $98.75
- P/E Ratio
- FULC N/A
- TTGT N/A
- Revenue Growth
- FULC 2752.05
- TTGT 50.73
- 52 Week Low
- FULC $2.32
- TTGT $5.39
- 52 Week High
- FULC $9.88
- TTGT $33.08
- Technical
- Relative Strength Index (RSI)
- FULC 54.66
- TTGT 42.57
- Support Level
- FULC $9.10
- TTGT $5.58
- Resistance Level
- FULC $9.88
- TTGT $6.21
- Average True Range (ATR)
- FULC 0.57
- TTGT 0.39
- MACD
- FULC -0.02
- TTGT -0.02
- Stochastic Oscillator
- FULC 56.24
- TTGT 10.81
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
About TTGT TechTarget Inc.
TechTarget Inc is engaged in the business-to-business (B2B) accelerator, informing and influencing technology buyers and sellers. Through its B2B first-party data and an end-to-end portfolio of data-driven solutions, it services the full B2B product lifecycle for customers from, messaging, and content development to in-market activation via brand, demand generation, purchase intent data, and sales enablement from R&D to ROI.